Dariohealth CORP 8-K filings

DarioHealth Corp. announced the pricing of a registered direct offering, raising approximately $23.5 million through the sale of common stock and pre-funded warrants.

DarioHealth Corp. announced on July 10, 2026, that the medical leave of absence for Steven Nelson, President and Chief Commercial Officer, has been extended indefinitely, with his duties temporarily reassigned.

DarioHealth Corp. announced the appointment of John R. Palumbo to its Board of Directors, leveraging his extensive healthcare operating experience to support the company's commercial scaling.

DarioHealth Corp. has amended its Certificate of Incorporation to explicitly grant its Board of Directors the power to alter and repeal company bylaws, a change approved by stockholders.

DarioHealth Corp. stockholders approved the election of directors, auditor ratification, preferred share conversions, Twill acquisition share issuances, and an increase in the equity incentive plan at their 2026 Annual Meeting.

DarioHealth Corp. has amended its credit agreement with Callodine Commercial Finance, resetting financial covenants, adjusting liquidity requirements, and modifying warrant terms.

DarioHealth Corp. announced a $17.5 million private placement, the mandatory conversion of Series C-1 Preferred Stock, and the initiation of a comprehensive strategic review to maximize shareholder value.

DarioHealth Corp. has amended its preferred stock certificates, accelerating the mandatory conversion of Series A-1, C, C-2, D, D-1, D-2, and D-3 preferred shares into common stock or pre-funded warrants, effective September 18, 2025.

DarioHealth Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter of its previous non-compliance.

DarioHealth Corp. will effect a 20-for-1 reverse stock split of its common stock, effective August 28, 2025, to reduce outstanding shares.

DarioHealth Corp. stockholders approved all five proposals at the 2025 Annual Meeting, including the election of directors, auditor ratification, an amended equity compensation plan, a reverse stock split authorization, and an increase in authorized common stock.

DarioHealth Corp. has appointed Steven M. Nelson, its current Chief Commercial Officer, to the additional role of President, effective July 10, 2025, leveraging his extensive leadership experience in the healthcare sector.

DarioHealth Corp. has filed an 8-K detailing amendments to its Series A-1 and B-1 Preferred Stock terms, allowing dividend payments in pre-funded warrants, and extending lock-up agreements for Series B and C Preferred Stock holders until February 2026 in exchange for additional common stock consideration.

DarioHealth Corp. has amended the terms of its Series C, C-1, and C-2 Preferred Stock, extending the mandatory conversion period and adjusting dividend terms.

DarioHealth Corp. has entered into a credit agreement for $32.5 million with the possibility of borrowing an additional $17.5 million, aimed at satisfying prior debt and supporting general business operations.

DarioHealth Corp. stockholders approved the issuance of common stock related to preferred stock conversions, dividends, and lock-up agreements, as well as the reduction of exercise price for certain warrants and conversion of a loan.

DarioHealth Corp. announces the resignation of CFO Zvi Ben-David, effective May 15, 2025, and the appointment of Chen Franco-Yehuda as the new CFO, also effective May 15, 2025.

DarioHealth Corp. has been granted an extension by Nasdaq to regain compliance with the minimum bid price requirement for continued listing.

DarioHealth Corp. has replaced Ernst & Young (EY) with PricewaterhouseCoopers (PwC) as its independent registered public accounting firm, effective March 12, 2025.

DarioHealth Corp. appoints Lawrence Leisure, a healthcare industry veteran, to its Board of Directors to leverage his expertise in advancing the company's AI-driven chronic care platform.

DarioHealth announces a $25.6 million private placement aimed at achieving an operational cash flow positive run rate by the end of 2025.

DarioHealth Corp. has entered into securities purchase agreements for a private placement offering, raising approximately $6.824 million through the sale of Series D-2 and Series D-3 Preferred Stock.

DarioHealth Corp. has successfully raised approximately $18.8 million through a private placement of preferred stock and amended its loan agreement, extending its cash runway.

DarioHealth Corp. held its 2024 Annual Meeting of Stockholders on December 18, 2024, where directors were elected and the company's auditors were ratified.

DarioHealth Corp. has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock price has remained below $1 for 30 consecutive business days.

DarioHealth Corp. has amended the terms of its Series B-3 Preferred Stock, extending the mandatory conversion period and increasing dividend percentages for holders.

DarioHealth Corp. has amended the terms of its Series B and Series B-1 Preferred Stock, extending the mandatory conversion period and increasing dividend percentages.

DarioHealth Corp. stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing the number of issuable shares by 3,000,000, and also approved the issuance of shares related to the Twill Inc. acquisition.

DarioHealth Corp. has appointed Steven Nelson as its new Chief Commercial Officer, effective June 5, 2024, while Richard Anderson has stepped down as President.

DarioHealth Corp. has finalized its acquisition of Twill, Inc., and released pro forma financial statements reflecting the combined entity's performance.